دورية أكاديمية
Attainment of Target Antibiotic Levels by Oral Treatment of Left-Sided Infective Endocarditis: A POET Substudy.
| العنوان: | Attainment of Target Antibiotic Levels by Oral Treatment of Left-Sided Infective Endocarditis: A POET Substudy. |
|---|---|
| المؤلفون: | Bock M; Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Theut AM; Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., van Hasselt JGC; Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands., Wang H; Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark., Fuursted K; Department of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark., Høiby N; Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark., Lerche CJ; Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Clinical Microbiology, Copenhagen University Hospital, Hvidovre, Denmark., Ihlemann N; Department of Cardiology, Bispebjerg Hospital, Copenhagen, Denmark., Gill S; Department of Cardiology, Odense University Hospital, Odense, Denmark., Christiansen U; Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark., Nielsen HL; Department of Clinical Microbiology, Aalborg University Hospital, Aalborg, Denmark.; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark., Lemming L; Department of Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark., Elming H; Department of Cardiology, Zealand University Hospital, Roskilde, Denmark., Povlsen JA; Department of Cardiology, Aarhus University Hospital, Aarhus N, Denmark., Bruun NE; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.; Department of Cardiology, Zealand University Hospital, Roskilde, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Høfsten D; Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Fosbøl EL; Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Køber L; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.; Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Schultz M; Department of Internal Medicine, Copenhagen University Hospital, Herlev-Gentofte, Copenhagen, Denmark., Pries-Heje MM; Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Kristensen JH; Department of Cardiology, Copenhagen University Hospital, Herlev-Gentofte, Copenhagen, Denmark.; Department of Emergency Medicine, Copenhagen University Hospital, Herlev-Gentofte, Copenhagen, Denmark., Christensen JJ; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.; The Regional Department of Clinical Microbiology, Region Zealand, Denmark., Rosenvinge FS; Department of Clinical Microbiology, Odense University Hospital, Odense, Denmark.; Research Unit of Clinical Microbiology, University of Southern Denmark, Odense, Denmark., Pedersen CT; Department of Cardiology, Nordsjællands Hospital, Hillerød, Denmark.; Department of Public Health, University of Copenhagen, Copenhagen, Denmark., Helweg-Larsen J; Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Tønder N; Department of Cardiology, Nordsjællands Hospital, Hillerød, Denmark., Iversen K; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.; Department of Emergency Medicine, Copenhagen University Hospital, Herlev-Gentofte, Copenhagen, Denmark., Bundgaard H; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.; Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark., Moser C; Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.; Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark. |
| المصدر: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2023 Jul 26; Vol. 77 (2), pp. 242-251. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Jan. 2011- : Oxford : Oxford University Press Original Publication: Chicago, IL : The University of Chicago Press, c1992- |
| مواضيع طبية MeSH: | Endocarditis*/drug therapy , Endocarditis, Bacterial*/drug therapy , Endocarditis, Bacterial*/microbiology, Humans ; Rifampin/therapeutic use ; Dicloxacillin/therapeutic use ; Linezolid/therapeutic use ; Moxifloxacin/therapeutic use ; Anti-Bacterial Agents/pharmacology ; Amoxicillin ; Microbial Sensitivity Tests |
| مستخلص: | Background: In the POET (Partial Oral Endocarditis Treatment) trial, oral step-down therapy was noninferior to full-length intravenous antibiotic administration. The aim of the present study was to perform pharmacokinetic/pharmacodynamic analyses for oral treatments of infective endocarditis to assess the probabilities of target attainment (PTAs). Methods: Plasma concentrations of oral antibiotics were measured at day 1 and 5. Minimal inhibitory concentrations (MICs) were determined for the bacteria causing infective endocarditis (streptococci, staphylococci, or enterococci). Pharmacokinetic/pharmacodynamic targets were predefined according to literature using time above MIC or the ratio of area under the curve to MIC. Population pharmacokinetic modeling and pharmacokinetic/pharmacodynamic analyses were done for amoxicillin, dicloxacillin, linezolid, moxifloxacin, and rifampicin, and PTAs were calculated. Results: A total of 236 patients participated in this POET substudy. For amoxicillin and linezolid, the PTAs were 88%-100%. For moxifloxacin and rifampicin, the PTAs were 71%-100%. Using a clinical breakpoint for staphylococci, the PTAs for dicloxacillin were 9%-17%.Seventy-four patients at day 1 and 65 patients at day 5 had available pharmacokinetic and MIC data for 2 oral antibiotics. Of those, 13 patients at day 1 and 14 patients at day 5 did only reach the target for 1 antibiotic. One patient did not reach target for any of the 2 antibiotics. Conclusions: For the individual orally administered antibiotic, the majority reached the target level. Patients with sub-target levels were compensated by the administration of 2 different antibiotics. The findings support the efficacy of oral step-down antibiotic treatment in patients with infective endocarditis. Competing Interests: Potential conflicts of interest. C. T. P. reports a grant from Bayer for a randomized study, and a grant from Novo Nordisk for an epidemiological study. L. K. reports payment for speaking engagements from AstraZeneca, Bayer, Boehringer, and Novartis. C. M. reports payment for speaking engagements from AstraZeneca, GSK, MSD, and Pfizer; co-authorship of the Danish Treatment Guidelines for Infective Endocarditis and of the ESCMID guidelines for prevention, treatment and diagnosis of biofilm infections; and service as a board member of the European Society for Clinical Microbiology Study Group (ESCMID) for Biofilms (ESGB). E. L. F. reports grants from Novo Nordisk Foundation and the Danish Heart Association. N. E. B. reports grants from Novo Nordisk Foundation, Health Insurance Denmark, and Augustinus Foundation (all unrelated to this study). F. S. R. reports unpaid positions on the Danish Ministry of Health's National expert advisory board on antimicrobial stewardship, the Region of Southern Denmark's Regional working group on antimicrobial stewardship, and chairman on the Steering committee and working group at Odense University Hospital for rational use of antimicrobial drugs. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2023. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.) |
| فهرسة مساهمة: | Keywords: infective endocarditis; oral antibiotics; pharmacodynamics; pharmacokinetics; target attainment |
| المشرفين على المادة: | VJT6J7R4TR (Rifampin) COF19H7WBK (Dicloxacillin) ISQ9I6J12J (Linezolid) U188XYD42P (Moxifloxacin) 0 (Anti-Bacterial Agents) 804826J2HU (Amoxicillin) |
| تواريخ الأحداث: | Date Created: 20230322 Date Completed: 20230728 Latest Revision: 20230729 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1093/cid/ciad168 |
| PMID: | 36947131 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1537-6591 |
|---|---|
| DOI: | 10.1093/cid/ciad168 |